Intelligent Health Lab Series: Dr. Dave Ferrucci

Speaker: Dave Ferrucci, PhD, at Elemental Cognition

Date: September 12, 2022 at 4:00PM - 5:00PM

Talk Topic: The Tale of Two AI's - From Vision to Market.

Dr. David Ferrucci is the award-winning Artificial Intelligence (“AI”) researcher who started and led the IBM Watson team from its inception in 2006 to its celebrated success in 2011 when Watson defeated the greatest Jeopardy players of all time. Considered a landmark in AI, Watson delivered amazing results that out-performed all expectations. From 2011 through 2012, Dr. Ferrucci pioneered Watson's applications in health which helped lay the technical foundation for a new Healthcare Division at IBM. In 2013, Dr. Ferrucci joined Bridgewater Associates to explore applied applications in markets and management. 

Dr. Ferrucci’s more than 25 years in AI and his passion to see computers fluently think, learn, and communicate inspired him to found Elemental Cognition in 2015. Elemental Cognition is an AI company focused on deep natural language understanding and explores methods of learning that result in explicable models of intelligence. 

Dr. Ferrucci graduated from Rensselaer Polytechnic Institute with a Ph.D. in Computer Science. He has 50+ patents and published papers in the areas of AI, Automated Reasoning, NLP, Intelligent Systems Architectures, Automatic Text Generation, and Automatic Question-Answering. He led numerous projects prior to Watson including AI systems for manufacturing, configuration, document generation, and standards for large-scale text and multi-modal analytics. Dr. Ferrucci has keynoted in highly distinguished venues around the world including many of the top computing conferences. He has been interviewed by numerous media outlets including: The New York Times, PBS, Financial Times, Bloomberg and the BBC. Dr. Ferrucci was awarded the title of IBM Fellow and has won many prestigious awards for his work.


Publications

Hopper RK, Abman SH, Elia EG, Avitabile CM, Yung D, Mullen MP, Austin ED, Bates A, Handler SS, Feinstein JA, Ivy DD, Kinsella JP, Mandl KD, Raj JU, Sleeper LA, . Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry. The Journal of pediatrics 2022.

Wang X, Zhang HG, Xiong X, Hong C, Weber GM, Brat GA, Bonzel CL, Luo Y, Duan R, Palmer NP, Hutch MR, Gutiérrez-Sacristán A, Bellazzi R, Chiovato L, Cho K, Dagliati A, Estiri H, García-Barrio N, Griffier R, Hanauer DA, Ho YL, Holmes JH, Keller MS, Klann MEng JG, L'Yi S, Lozano-Zahonero S, Maidlow SE, Makoudjou A, Malovini A, Moal B, Moore JH, Morris M, Mowery DL, Murphy SN, Neuraz A, Yuan Ngiam K, Omenn GS, Patel LP, Pedrera-Jiménez M, Prunotto A, Jebathilagam Samayamuthu M, Sanz Vidorreta FJ, Schriver ER, Schubert P, Serrano-Balazote P, South AM, Tan ALM, Tan BWL, Tibollo V, Tippmann P, Visweswaran S, Xia Z, Yuan W, Zöller D, Kohane IS, Avillach P, Guo Z, Cai T, . SurvMaximin: Robust federated approach to transporting survival risk prediction models. Journal of biomedical informatics 2022.

Torous J, Stern AD, Bourgeois FT. Regulatory considerations to keep pace with innovation in digital health products. NPJ digital medicine 2022.

Levy S, Wisk LE, Minegishi M, Ertman B, Lunstead J, Brogna M, Weitzman ER. Association of Screening and Brief Intervention With Substance Use in Massachusetts Middle and High Schools. JAMA network open 2022.

Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Co-existing alterations of MHC class I antigen presentation and IFNγ signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy. Cancer immunology research 2022.